Fig. 4: iASPP is a paradoxical suppressor of oncogenic KRAS- and inflammation-induced ADM in vivo.
From: p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
A Acinar-to-ductal metaplasia efficiency on day 5 of cultured Pdx1-Cre; iASPP+/+ (n = 2) and Pdx1-Cre;iASPPΔ8/Δ8 (n = 3) pancreatic acini with and without TGFα stimulation. * = p < 0.05, using unpaired t-test. Inset images in graph are phase contrast of ADM assay. Acinus (left) with no evidence of ductal metaplasia and acinus having undergone ADM with ring morphology (right). B Acinar-to-ductal metaplasia efficiency on day 5 of cultured KC (n = 2) and KC;iASPPΔ8/Δ8 acini (n = 3) pancreatic acini with and without TGFα stimulation. **** = p < 0.0001 using unpaired t-test. C H&E staining of representative 12-week old KC and KC;iASPPΔ8/Δ8 normal acini and ADM (denoted by asterisk). Scale bar, 250 µm. D Quantification of ADM events per field in young (12- to 16-week old) KC (n = 5) and KC;iASPPΔ8/Δ8 (n = 4) mice. **** = p < 0.0001 using Mann-Whitney test. E Injection schedule of weekly caerulein (250 µg/kg) over 6 weeks followed by planned culling after 0-, 6- and 10-week recovery. F Representative H&E images of KC and KC;iASPPΔ8/Δ8 pancreas following weekly caerulein after 0-, 6-, and 10-weeks recovery. Inset image is magnified dotted box. Black arrows indicate ADM in progress. Scale bars, 250 µm (main images) and 50 µm (inset images).
